Plexiform neurofibroma care at Mayo Clinic

Mayo Clinic's world-renowned Neurofibromatosis Clinic provides coordinated care for people with this complex condition, including those with plexiform neurofibroma. Geneticists, adult and pediatric neurologists, neuro-oncologists, radiologists, and neurosurgeons work together to provide exactly the care you need. Genetic counselors, ophthalmologists, orthopedic surgeons, dermatologists, pain medicine experts, and ear, nose and throat specialists also are part of the treatment team.

Mayo Clinic in Rochester, Minnesota, also offers the family-friendly Children's for children with plexiform neurofibroma.

Having all of this subspecialized expertise in a single place, focused on you, means that you're not just getting one opinion. Care is discussed among the team members, appointments are scheduled in coordination and highly specialized plexiform neurofibroma experts are all working together to determine what's best for you.

What might take months to accomplish elsewhere can typically be done in a matter of only days at Mayo Clinic.

Advanced diagnosis and treatment

Mayo Clinic doctors have access to the latest imaging and diagnostic tools, and there's a long history of Mayo Clinic scientists developing cutting-edge technologies for patient care.

Mayo Clinic specialists use a comprehensive range of genetic testing, imaging, and vision and hearing assessments to diagnose plexiform neurofibroma. Mayo Clinic experts also offer advanced treatment options for plexiform neurofibroma, including specialized surgical care.

The Neurofibromatosis Clinic also has genetic counselors who can help you make decisions that are appropriate for you and your family. Counselors can help you consider risks, family goals, and ethical and religious standards when making treatment decisions.

Aug. 19, 2025
  1. Plexiform neurofibroma. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/plexiform-neurofibroma. Accessed July 18, 2025.
  2. Korf BR. Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis. https://www.uptodate.com/contents/search. Accessed July 18, 2025.
  3. Yang X, et al. Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA. Child's Nervous System. 2022; doi:10.1007/s00381-022-05513-8.
  4. Adam MP, et al., eds. Neurofibromatosis. In: GeneReviews. University of Washington, Seattle; 1993-2025. https://www.ncbi.nlm.nih.gov/books/NBK1116/. Accessed July 21, 2025.
  5. Neurofibromatosis. National Institute of Neurological Disorders and Stroke. https://www.ninds.nih.gov/health-information/disorders/neurofibromatosis. Accessed July 22, 2025.
  6. Copley-Merriman C, et al. Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: A systematic literature review. Adolescent Health, Medicine and Therapeutics. 2021; doi:10.2147/AHMT.S303456.
  7. AskMayoExpert. Neurofibromatosis 1 management. Mayo Clinic; 2025.
  8. Bergqvist C, et al. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet Journal of Rare Diseases. 2020; https://doi.org/10.1186/s13023-020-1310-3.
  9. de Blank PMK, et al. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro‑Oncology. 2022; doi:10.1093/neuonc/noac165.
  10. Moertel CL et al. ReNeu: A pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. Journal of Clinical Oncology. 2025; doi:10.1200/JCO.24.01034.
  11. Gross AM et al. Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: A phase 2 trial. Nature Medicine. 2025; doi:10.1038/s41591‑024‑03361‑4.
  12. Fisher MJ, et al. Management of neurofibromatosis type 1‑associated plexiform neurofibromas. Neuro‑Oncology. 2022; doi:10.1093/neuonc/noac146.
  13. Medical review (expert opinion). Mayo Clinic. Aug. 3, 2025.